Cidara Therapeutics, Inc. (CDTX) NASDAQ

Currency In USD

Cidara Therapeutics, Inc.

Address

6310 Nancy Ridge Drive

San Diego, CA 92121

United States of America (the)

Phone

858 752 6170

Website

https://www.cidara.com

Sector

Healthcare

Industry

Biotechnology

Employees

First IPO Date

April 15, 2015

Key Executives

Name	Title	Pay	Year Born
Jeffrey L. Stein	President, Chief Executive Officer & Executive Director	1.1M	1955
Kevin Forrest	Founder & Chief Strategy Officer	333,313	1977
Preetam Shah	Principal Accounting Officer	577,850	1973
Shane Ward	Chief Operating Officer & Corporate Secretary	620,940	1975
Nicole Davarpanah	Chief Medical Officer	664,600	N/A
Leslie Tari	Chief Scientific Officer	688,050	1967
Jim Beitel	Chief Business Officer	0	N/A
Allison Lewis SPHR	Senior Vice President of People & Culture	0	N/A
Corrina Pavetto	Senior Vice President of Clinical Development	0	N/A
Frank L. Karbe	Chief Financial Officer	0	1968

Description

Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.